| アブストラクト | BACKGROUND: Faricimab is a bispecific antibody targeting vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), offering a novel therapeutic approach for ocular diseases. However, its long-term safety profile remains under evaluation. This study analyzes its adverse events (AEs) using the U.S. FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER). METHODS: AEs from FAERS (2004-2024) and JADER (2004-2024) were analyzed using disproportionality algorithms. Subgroup analyses assessed differences by age and sex. AE onset time was also assessed. RESULTS: Several newly identified adverse events (AEs) were observed, including macular ischemia, keratic precipitates, and optic nerve injury, with strong safety signals detected in both FAERS and JADER. For instance, macular ischemia showed a high association with faricimab use (ROR = 260.46), suggesting a potential risk of retinal circulation impairment. Similarly, keratic precipitates (ROR = 739.65) indicate a notable inflammatory response. All these findings highlight the need for closer monitoring of ocular complications, particularly in high-risk patient groups. The FAERS database mainly reported retinal occlusive vasculitis, ocular vasculitis, and keratic precipitates, while JADER predominantly featured retinal occlusive vasculitis and retinal vascular occlusion. Sex-based differences indicated a higher risk of inflammatory AEs in females (e.g., uveitis and eye inflammation) and a greater incidence of retinal vascular events in males (e.g., retinal vasculitis). Age-related differences showed that older patients (>/=65 years) had lower inflammatory AE risks but were more prone to optic nerve damage and retinal atrophy, while younger patients (<65 years) exhibited a higher risk of vitreous hemorrhage and cataracts. CONCLUSIONS: This study identified previously unreported safety signals, suggesting the need for potential updates to faricimab's safety labeling. Faricimab's dual-target mechanism presents unique safety concerns. Clinicians should monitor ocular inflammation and vascular complications, particularly in younger males and Asian patients. Further studies using real-world data are needed to validate these findings. |
|---|
| ジャーナル名 | BMC pharmacology & toxicology |
|---|
| Pubmed追加日 | 2025/4/13 |
|---|
| 投稿者 | Liu, Chuanya; Li, Shangze; Wang, Ziyi; Li, Zhifu; Fang, Zhou; Zhang, Yuan; Gao, Yu |
|---|
| 組織名 | Department of Ophthalmology, The First Affiliated Hospital (Shanghai Changhai;Hospital), Naval Medical University, Shanghai, China.;Department of Orthopedics, Changzhou Medical District, No. 904 Hospital of PLA;Joint Logistic Support Force, Changzhou, China.;Hospital), Naval Medical University, Shanghai, China. changhaizhy@aliyun.com.;Hospital), Naval Medical University, Shanghai, China. gaoyu@smmu.edu.cn. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40221797/ |
|---|
